Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Gilead Sciences Develops And Markets Therapies To Treat And Prevent Life-Threatening Infectious Diseases, With The Core Of Its Portfolio Focused On Hiv And Hepatitis B And C. Gilead'S Acquisition Of Pharmasset Brought Rights To Hepatitis C Drug Sovaldi, Which Is Also Part Of Newer Combination Regimens That Remain Standards Of Care. Gilead Is Also Growing Its Presence In The Oncology Market Via Acquisitions, Led By Car-T Cell Therapy Yescarta/Tecartus (From Kite) And Breast And Bladder Cancer Therapy Trodelvy (From Immunomedics).